Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease experts
Strasbourg, France, June 24, 2019 – Domain Therapeutics today announces the appointment of world-renowned G protein-coupled receptors (GPCR) and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer. Dr. Youssef Bennani, chairman of Domain’s board of directors, will also join the SAB, which will benefit from his expertise in drug discovery and development acquired during 25 years in the pharmaceutical R&D industry, including 15 years at Vertex Pharmaceuticals.
Since its inception, Domain Therapeutics has initiated and developed high-value innovative programs targeting GPCRs, with the aim of bringing novel therapies to patients in the fields of neurodegenerative disorders, oncology/immuno-oncology and rare diseases. In addition to its expertise in the identification and early development of small molecule drug candidates, the company is also building additional capabilities in biologics through collaborations.
The SAB, chaired by Pr. Michel Bouvier, will provide valuable scientific insight and recommendations to Domain’s management team to ensure the rapid expansion of its pipeline and to progress existing and future assets from discovery to the clinical phase.
Share this article